Centro Hospitalar Universitario Sao Joao E.P.E.
- Address
- lock Available on a paid plan
Digestive System Diseases
The gastroenterology unit is evaluating new oral therapies to maintain remission in patients with Crohn's disease.
- Upadacitinib as maintenance therapy
- Long‑term safety monitoring
- Patient‑reported outcomes
- Dose optimization strategies
At Centro Hospitalar Universitario Sao Joao E.P.E. more than 80 investigators contribute to a portfolio of 10 active studies.
Nervous System Diseases
A precision‑medicine study targets motor decline in individuals with Parkinson’s disease carrying a GBA1 mutation.
- Genotype‑guided therapy
- Motor function scales
- Safety and tolerability assessments
- Impact on daily living
The trial aims to improve quality of life for patients while advancing personalized treatment options.
Cardiovascular Diseases
A comparative trial examines whether asundexian can safely reduce stroke risk in patients with atrial fibrillation.
- Efficacy in preventing stroke
- Major bleeding outcomes
- Benefit‑risk balance
- Patient adherence
Findings will inform anticoagulation strategies for individuals at high risk of thrombo‑embolic events.
Virus Diseases
Researchers assess continued viral suppression after switching to a simplified DTG/3TC regimen in treatment‑experienced adults living with HIV.
- Virologic control
- Safety profile
- Treatment convenience
- Long‑term outcomes
The study supports therapeutic options that reduce pill burden for aging patients.
Congenital, Hereditary, and Neonatal Diseases
A gene‑therapy approach is being tested for safety and copper regulation in patients with Wilson disease. Parallel research evaluates long‑term prophylaxis with a novel agent in individuals with haemophilia A.
- Gene delivery vectors
- Copper excretion monitoring
- Inhibitor management strategies
- Pediatric safety data
Collaboration across several European countries enhances the robustness of these rare‑disease investigations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 23 therapeutic areas and 15 of 228 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 223 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 39 by active trials.
lock +38 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG15trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar Universitario Sao Joao E.P.E.
lock Showing 1 of 146 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 228 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2022-08-18 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.